Back to top

Image: Bigstock

Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility

Read MoreHide Full Article

Key Takeaways

  • New coverage sparks focus on KALA, GHM, ARQ, and HWKN amid economic and earnings uncertainty.
  • KALA shares jumped 96.1% in 3 months; the 2025 loss per share estimate narrowed over the past 30 days.
  • GHM gained 75.2% in 3 months with a rising EPS estimate; ARQ and HWKN also outperformed peers recently.

In the current backdrop of heightened economic uncertainty—marked by tariff volatility, inflationary pressure, and growing concerns over policy interference—new analyst coverage plays a crucial role in guiding investors through volatility. Fresh coverage often brings updated insights into company fundamentals, risk exposures, and sector resilience, particularly valuable as macro signals grow more conflicting. As corporate earnings become harder to predict, timely and independent coverage becomes essential to help investors reassess valuations, capitalize on dislocations, and identify defensive or opportunistic plays.

New analyst coverage provides timely insights, updated models, and context on how companies might fare amid inflationary pressures, cost volatility, and weakening demand. Recent initiations on KALA BIO, Inc. (KALA - Free Report) , Graham Corporation (GHM - Free Report) , Arq, Inc. (ARQ - Free Report) and Hawkins, Inc. (HWKN - Free Report) reflect this growing need for sharper analysis, potentially boosting investor interest in these names.

Why New Analyst Coverage Holds Weight

Analysts typically possess specialized knowledge and expertise in particular industries or sectors. Through thorough research and analysis, they offer investors critical insights into a company's financial health, growth potential, competitive standing, and industry trends — insights that are often difficult for individual investors to acquire independently.

Coverage initiation on a stock by analyst(s) usually portrays a higher investor inclination. Investors, on their part, often assume that there is something special in a stock to attract analysts to cover it. In other words, they believe that the company coming under the microscope definitely holds some value.

Do analysts create value for companies by initiating coverage? Of course, they do because they play an important intermediary role with their extensive access to relevant data. Many investors have immense faith in analysts’ research as they fear that a lack of information might trigger inefficiencies.

Obviously, stocks are not randomly chosen to cover. A new coverage on a stock usually reflects a reassuring future envisioned by the analyst(s). At times, increased investor focus on a stock motivates analysts to take a closer look at it. After all, who doesn’t like to produce something that is already in demand? Hence, we often find that analysts’ ratings on newly added stocks are more favorable than their ratings on continuously covered stocks.

Needless to say, the average change in broker recommendation is preferable to a single recommendation change. Again, if an analyst issues a new recommendation on a company that has very little or no existing coverage, investors start paying more attention to it. Also, any further information attracts portfolio managers to build a position in the stock.

Stock Price Movements and Market Impact

New analyst coverage often leads to immediate stock price volatility. A positive rating can attract bullish sentiment and drive share prices higher, while neutral or negative ratings may trigger sell-offs. When multiple analysts initiate favorable coverage, the resulting investor confidence can lead to sustained upward momentum in valuation. Conversely, if coverage highlights overlook risks, investor enthusiasm may be dampened, and long-term performance can be hindered.

Are there newly covered stocks on your radar? Now might be the perfect time to dig deeper and uncover your next winning investment.

So, it’s a good strategy to bet on stocks that have seen increased analyst coverage over the last few weeks.

Screening Criteria

The Number of Broker Ratings is greater than the Number of Broker Ratings four weeks ago (this will shortlist stocks that have recent new coverage).

Average Broker Rating less than Average Broker Rating four weeks ago (“less than” means “better than” four weeks ago).

Increased analyst coverage and improving average rating are the primary criteria of this strategy, but one should also consider other relevant parameters to make it foolproof.

Here are the other screening parameters:

Price greater than or equal to $5 (as a stock below $5 will not likely create significant interest for most investors).

Average Daily Volume greater than or equal to 100,000 shares (if the volume isn’t enough, it will not attract individual investors).

Here are four out of six stocks that passed the screen:

KALA BIO: Based in Arlington, MA, this is a clinical-stage biopharmaceutical company. KALA BIO currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

KALA BIO shares have gained 96.1% in the past three months, much above the industry’s 6.7% rise. The 2025 loss per share estimate has narrowed to $5.25 from $5.66 over the past 30 days, depicting analysts’ optimism over the company’s prospects. The estimated figure for 2025 indicates improvement from the year-ago reported loss of $10.15 per share. 

Graham: Based in Batavia, NY, Graham designs fluid, power, heat transfer, and vacuum systems for industries including chemical processing, defense, space, and energy. Graham currently carries a Zacks Rank #3 (Hold).

Graham shares have gained 75.2% in the past three months, outperforming the industry’s 16.8% rise. The fiscal 2026 EPS estimate has increased to $1.23 from $1.18 over the past 60 days. The estimated figure for fiscal 2026 indicates a 0.8% year-over-year decline on 9.7% revenue growth.

Arq:  Headquartered in Greenwood Village, CO, Arq is an environmental technology company. Arq currently carries a Zacks Rank #3.

Arq shares have gained 57% in the past three months, outperforming the industry’s 1.9% growth. The 2025 EPS estimate has remained unchanged at 6 cents per share over the past 30 days. The estimated figure for 2025 indicates quite an improvement from the year-ago reported loss per share of 14 cents.

Hawkins: Headquartered in Roseville, MN, this company operates as a water treatment and specialty ingredients company. The company currently carries a Zacks Rank #3.

Hawkins has gained 25.6% in the past three months, outperforming the industry’s 7.5% rise. The 2025 EPS estimate has remained unchanged at $4.37 over the past 60 days. The estimated figure for 2025 indicates an 8.4% year-over-year decline. Yet, Hawkins carries an impressive VGM Score of B.

You can get the remaining stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your trading. Further, you can also create your strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial of the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Graham Corporation (GHM) - free report >>

Hawkins, Inc. (HWKN) - free report >>

KALA BIO, Inc. (KALA) - free report >>

Arq, Inc. (ARQ) - free report >>

Published in